JP2016511261A - 鉄欠乏性貧血の迅速かつ効果的な治療のための鉄系ナノ複合材料の新規な製剤 - Google Patents

鉄欠乏性貧血の迅速かつ効果的な治療のための鉄系ナノ複合材料の新規な製剤 Download PDF

Info

Publication number
JP2016511261A
JP2016511261A JP2015560555A JP2015560555A JP2016511261A JP 2016511261 A JP2016511261 A JP 2016511261A JP 2015560555 A JP2015560555 A JP 2015560555A JP 2015560555 A JP2015560555 A JP 2015560555A JP 2016511261 A JP2016511261 A JP 2016511261A
Authority
JP
Japan
Prior art keywords
iron
nanocomposite
vitamin
anemia
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015560555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016511261A5 (cg-RX-API-DMAC7.html
Inventor
バクル モハメド マフムード，モナ
バクル モハメド マフムード，モナ
ハッサン アッバース ヘルミー，シェリーン
ハッサン アッバース ヘルミー，シェリーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
European Egyptian Pharmaceutical Industries Eepi
Nanotech For Photoelectronics Research
Original Assignee
European Egyptian Pharmaceutical Industries Eepi
Nanotech For Photoelectronics Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by European Egyptian Pharmaceutical Industries Eepi, Nanotech For Photoelectronics Research filed Critical European Egyptian Pharmaceutical Industries Eepi
Publication of JP2016511261A publication Critical patent/JP2016511261A/ja
Publication of JP2016511261A5 publication Critical patent/JP2016511261A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2015560555A 2013-03-06 2013-10-29 鉄欠乏性貧血の迅速かつ効果的な治療のための鉄系ナノ複合材料の新規な製剤 Pending JP2016511261A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EG2013030371 2013-03-06
EG2013030371 2013-03-06
PCT/EG2013/000027 WO2014135170A1 (en) 2013-03-06 2013-10-29 Novel formula of iron based nanocomposites for rapid and efficient treatment of iron deficiency anemia

Publications (2)

Publication Number Publication Date
JP2016511261A true JP2016511261A (ja) 2016-04-14
JP2016511261A5 JP2016511261A5 (cg-RX-API-DMAC7.html) 2016-06-02

Family

ID=51490651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015560555A Pending JP2016511261A (ja) 2013-03-06 2013-10-29 鉄欠乏性貧血の迅速かつ効果的な治療のための鉄系ナノ複合材料の新規な製剤

Country Status (6)

Country Link
US (1) US20160022733A1 (cg-RX-API-DMAC7.html)
EP (1) EP2964205A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016511261A (cg-RX-API-DMAC7.html)
CN (1) CN105101957A (cg-RX-API-DMAC7.html)
BR (1) BR112015021212A2 (cg-RX-API-DMAC7.html)
WO (1) WO2014135170A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190010265A (ko) * 2017-07-21 2019-01-30 태이생명과학 주식회사 마그헤마이트-사포닌 나노결합체를 유효성분으로 함유하는 조혈기능 장애 질환 예방 또는 치료용 약학조성물

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109602914B (zh) * 2019-01-08 2022-05-17 扬州大学 维生素b2修饰的铁基纳米酶及其制备方法和应用
JP2025537773A (ja) 2022-11-10 2025-11-20 ユニベルシテ ドゥ ロレーヌ 鉄ナノクラスター、それを得る方法及び鉄欠乏症への対処におけるその使用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065521A1 (en) * 2005-09-19 2007-03-22 Bala Venkataraman Composition and method for treating iron deficiency anemia
JP2008081891A (ja) * 2006-09-27 2008-04-10 Dainippon Printing Co Ltd 壁紙
WO2009120702A2 (en) * 2008-03-25 2009-10-01 Emory University Elemental iron nanoparticles
WO2010034319A1 (en) * 2008-09-29 2010-04-01 Innovative Research And Development Co. (Inrad) Magnetite nanoparticles as a single dose treatment for iron deficiency anemia
WO2012092305A2 (en) * 2010-12-27 2012-07-05 Incube Labs, Llc Nanonized iron compositions and methods of use thereof
CN102730767A (zh) * 2012-06-13 2012-10-17 湖北工业大学 一种纳米α-氧化铁粉体的快速制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI321133B (en) * 2006-08-01 2010-03-01 Univ Kaohsiung Medical Folate-receptor-targeting iron oxide nanoparticles coated with poly(ethylene glycol)

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065521A1 (en) * 2005-09-19 2007-03-22 Bala Venkataraman Composition and method for treating iron deficiency anemia
JP2008081891A (ja) * 2006-09-27 2008-04-10 Dainippon Printing Co Ltd 壁紙
WO2009120702A2 (en) * 2008-03-25 2009-10-01 Emory University Elemental iron nanoparticles
WO2010034319A1 (en) * 2008-09-29 2010-04-01 Innovative Research And Development Co. (Inrad) Magnetite nanoparticles as a single dose treatment for iron deficiency anemia
WO2012092305A2 (en) * 2010-12-27 2012-07-05 Incube Labs, Llc Nanonized iron compositions and methods of use thereof
CN102730767A (zh) * 2012-06-13 2012-10-17 湖北工业大学 一种纳米α-氧化铁粉体的快速制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190010265A (ko) * 2017-07-21 2019-01-30 태이생명과학 주식회사 마그헤마이트-사포닌 나노결합체를 유효성분으로 함유하는 조혈기능 장애 질환 예방 또는 치료용 약학조성물
KR102085115B1 (ko) 2017-07-21 2020-03-05 스노우화이트팩토리(주) 마그헤마이트-사포닌 나노결합체를 유효성분으로 함유하는 조혈기능 장애 질환 예방 또는 치료용 약학조성물

Also Published As

Publication number Publication date
CN105101957A (zh) 2015-11-25
US20160022733A1 (en) 2016-01-28
BR112015021212A2 (pt) 2017-07-18
EP2964205A1 (en) 2016-01-13
EP2964205A4 (en) 2016-07-27
WO2014135170A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
Kumari et al. Iron nanoparticles as a promising compound for food fortification in iron deficiency anemia: a review
JP7465313B2 (ja) がん放射線療法を増強するための組成物および方法
Scott et al. Copper nanoparticles as an alternative feed additive in poultry diet: a review
Olivares et al. Acute inhibition of iron bioavailability by zinc: studies in humans
JP2025120284A (ja) 魚油とセレンとを含む栄養サプリメント
Elshemy Iron oxide nanoparticles versus ferrous sulfate in treatment of iron deficiency anemia in rats
Cholewińska et al. Comparison of the effect of dietary copper nanoparticles and one copper (II) salt on the metabolic and immune status in a rat model
Nagpal et al. Iron formulations in pediatric practice
EP3260421A1 (en) Composite mineralized ceramic material capable of producing active hydrogen healthcare water
Ghosh et al. Fortification of foods with nano-iron: its uptake and potential toxicity: current evidence, controversies, and research gaps
JP2016511261A (ja) 鉄欠乏性貧血の迅速かつ効果的な治療のための鉄系ナノ複合材料の新規な製剤
Zlotkin et al. Demonstrating zinc and iron bioavailability from intrinsically labeled microencapsulated ferrous fumarate and zinc gluconate Sprinkles in young children
Olivares et al. Copper and zinc interactions in anemia: a public health perspective
JP5931324B2 (ja) がん化学療法時に起こる酸化ストレス及び／又は副作用の軽減あるいはがん化学療法時の栄養状態を改善するための組成物
Díaz-Castro et al. Influence of several sources and amounts of iron on DNA, lipid and protein oxidative damage during anaemia recovery
Hilty et al. Nano‐structured minerals and trace elements for food and nutrition applications
Zahra et al. A note on the Biocompatibility of Zinc oxide Nanoparticles in male albino mice
Ibrahim et al. Stannous chloride induces alterations in body weight and hematological parameters in male rabbit.
Kumar et al. Effectiveness Of Vitamin C For Iron Supplementation In Patients With Iron Deficiency Anemia
EP3459550B1 (en) Injection composition comprising an iron dextran complex and vitamins for preventing and treating anemia
JP6815994B2 (ja) 血中ヘモグロビン増加用組成物
Huang et al. Chickpea seeds ferritin as a potential source in the treatment of iron deficiency anemia
US20220072081A1 (en) Methods of using iron-free supplements to enhance cytoprotection against anemia in humans
PL232677B1 (pl) Wodorozpuszczalne, inteligentne kompleksy złota (III) i zastosowanie wodorozpuszczalnych, inteligentnych kompleksów złota (III)
Mohamed et al. Osmoregulation and antioxidant effects of copper sulfate and propolis in red blood cells of male rats.

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20151022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170711